Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2022-04-25 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
关于公司未弥补亏损达到股本总额三分之一的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Nuosiland Biotechnology Co., Ltd. regarding the company's accumulated losses exceeding one-third of its paid-in capital. It includes details about the financial audit results, reasons for the losses, and the company's planned measures to address the situation. The document is relatively short (1283 characters) and serves as a formal disclosure of a significant financial condition rather than a full financial report or detailed financial statements. It does not contain comprehensive financial data or detailed analysis typical of annual or interim reports. This type of announcement is regulatory in nature, informing shareholders and the market about a material financial issue and the company's response. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-04-25 Chinese
关于第一期股权激励计划第一个行权期行权条件及第一期解除限售条件成就的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Northland Biotechnology Co., Ltd. regarding the achievement of conditions for the first exercise period of stock options and the lifting of restrictions on the first batch of restricted stocks under the company's first equity incentive plan. It details the approval procedures, conditions met, specific exercise and lifting details, and includes opinions from independent directors, the supervisory board, legal counsel, and financial advisors. The content focuses on the status and execution of a stock-based incentive plan, including share issuance and cancellation arrangements. This is a capital structure and financing-related update concerning stock options and restricted stock plans, not a full financial report, earnings release, or management discussion. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the equity incentive plan execution, not merely an announcement of a report or a regulatory filing. Hence, the classification is CAP with high confidence.
2022-04-25 Chinese
2021年度营业收入扣除事项的专项审核报告
Regulatory Filings
2022-04-25 Chinese
中泰证券股份有限公司关于对北京诺思兰德生物技术股份有限公司公司治理的专项核查报告
Governance Information Classification · 95% confidence The document is titled as a "公司治理专项核查报告" which translates to "Special Governance Inspection Report" for Beijing Nuosiland Biotechnology Co., Ltd. It references relevant laws such as the Company Law and Securities Law, and details the company's governance structure, internal controls, board composition, and compliance with regulations. The content focuses on governance practices, board and management qualifications, decision-making processes, and the absence of violations. It does not contain financial statements or quarterly/yearly financial results. The document is a detailed report on corporate governance and internal controls, fitting the category of Governance Information (CGR). The document length is 2868 characters, which is relatively short but contains substantive governance content rather than just an announcement or certification. Therefore, the best classification is CGR with high confidence.
2022-04-25 Chinese
独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled '2021 年度独立董事述职报告' which translates to '2021 Annual Independent Directors' Report'. It details the independent directors' attendance, opinions, and activities during the year 2021. The content focuses on the independent directors' duties, opinions on board matters, and compliance with regulations. It is a report on the independent directors' performance and opinions rather than a full annual report or financial statement. This type of document is typically classified under Board/Management Information (MANG) as it relates to board members' activities and governance roles. The document length is short (2019 characters), and it is not an announcement of a report but the report itself. Therefore, the best fit is MANG with high confidence.
2022-04-25 Chinese
续聘会计师事务所公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's intention to reappoint an accounting firm for the 2022 annual audit. It details the accounting firm's background, qualifications, and the board's approval process. There is no actual audit report or financial statements included, nor is there a detailed financial analysis. The document is relatively short (2999 characters) and serves as a formal announcement of the auditor reappointment rather than the audit report itself. Therefore, it does not qualify as an Audit Report (AR) or Annual Report (10-K). It is also not a certification or officer attestation document. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about auditor appointment.
2022-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.